Collaborations
Through global collaboration, strategic alliances, and a shared purpose, we drive meaningful progress in bladder cancer research, education, treatment, and advocacy. By uniting clinicians, researchers, and patient advocates, we work collectively to accelerate innovation and improve outcomes for patients worldwide.
The IBCG is thrilled to join forces with UroToday, a premier global hub for urology news and education. Together, we are committed to empowering patients through enhanced outreach and education on bladder cancer. By combining our strengths, we aim to equip patients with the latest information and resources they need to navigate their bladder cancer journey.
The IBCG is honored to partner with the Bladder Cancer Advocacy Network (BCAN), a leading force in patient advocacy and support. Together, we are committed to empowering bladder cancer patients and their families by providing resources, fostering a strong community, and advocating for improved research and treatment options. Through this collaboration, we strive to ensure that every individual affected by bladder cancer has access to the support and information they need to navigate their journey with confidence and hope.
The IBCG values our partnership with the World Bladder Cancer Patient Coalition (WBCPC), a global network dedicated to uniting patient organizations worldwide in the fight against bladder cancer. By collaborating with the WBCPC, we aim to continue our track record of creating a truly global community where people can work together to drive meaningful change in the fight against bladder cancer.
In 2021, the IBCG and the Global Society of Rare GU Tumors (GSRGT) forged a powerful alliance by forming a joint committee focused on rare variants of bladder cancer. Recognizing the growing global health concern of bladder cancer, particularly the increasing incidence of rare variants, this committee unites experts from both organizations to collaborate on vital research, education, and clinical trial endpoints. Our shared goal is to advance the understanding and treatment of rare bladder cancer histologic subtypes and genetic variants.